PUNE, India, June 19, 2017 /PRNewswire-iReach/ -- RnRMarketResearch.com adds "Pontine Glioma - Pipeline Review, H1 2017" to its store.
The report "Pontine Glioma - Pipeline Review, H1 2017" provides comprehensive information on the therapeutics under development for Pontine Glioma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
Companies discussed of the Pontine Glioma Pipeline Market are AbbVie Inc, Arog Pharmaceuticals Inc, AstraZeneca Plc, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Burzynski Research Institute Inc, Insys Therapeutics Inc, Loxo Oncology Inc, Medicenna Therapeutics Corp, Midatech Pharma Plc, Novogen Ltd, Ono Pharmaceutical Co Ltd, Pfizer Inc, Sanofi, ZIOPHARM Oncology Inc
Pontine Glioma - Drug Profiles : AdRTSIL-12, afatinib dimaleate, AZD-1775, cabazitaxel, cannabidiol, Cellular Immunotherapy for Pediatric Diffuse Intrinsic Pontine Glioma, crenolanib besylate, depatuxizumab mafodotin, larotrectinib, MDNA-55, MTX-110, MTX-111, nivolumab, p28, pidilizumab, Trilexium, VIMO-001
Order a copy of this research report at http://www.rnrmarketresearch.com/contacts/purchase?rname=1066587 .
Pontine gliomas are highly aggressive and difficult to treat brain tumors found at the base of the brain. One of the most common types is diffuse intrinsic pontine glioma (DIPG). DIPG affects the pons portion of the brainstem, rendering nervous system function impossible. Symptoms include double vision, inability to close the eyelids completely, dropping one side of the face, and difficulty chewing and swallowing.
The Pontine Glioma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Pontine Glioma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 6, 5, 7 and 2 respectively. Similarly, the Universities portfolio in Phase I stages comprises 2 molecules, respectively.
Pontine Glioma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Table of Contents:
List of Figures
Number of Products under Development for Pontine Glioma, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017
Adult Malignant Glioma Global Clinical Trials Review, H1, 2017 : Adult Malignant Glioma Global Clinical Trials Review, H1, 2017" provides an overview of Adult Malignant Glioma clinical trials scenario. This report provides top line data relating to the clinical trials on Adult Malignant Glioma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type.
Media Contact: Ritesh Tiwari, RnRMarketResearch.com, + 1 888 391 5441, firstname.lastname@example.org
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE RnR Market Research